Association of single nucleotide variants in the DRD3 and LINGO1 genes with the development of drug dyskinesias in Parkinson's disease: results of a pilot study
https://doi.org/10.25789/YMJ.2021.75.02
Abstract
The association of SNV rs6280 of the DRD3 gene and rs9652490 of the LINGO1 gene with the development of drug (levodopa-induced) dyskinesia (LD) in patients with Parkinson's disease (PD) was studied. The obtained results of the pilot study indicate the absence of a predictive role of the carriage of SNV rs6280 of the DRD3 gene and rs9652490 of the LINGO1 gene on the development of LD in PD patients living in the Republic of Sakha (Yakutia). However, the authors do not exclude the influence of a small sample size on outcomes of the associative genetic study.
Keywords
Parkinson disease,
movement disorders,
levodopa,
adverse reaction,
drug dyskinesia,
pharmacogenetics,
personalized medicine,
single nucleotide variant,
DRD3,
LINGO1
Supporting agencies: The study was supported by the Grant of the President of the Russian Federation for state support of young Russian scientists - candidates of sciences and doctors of sciences and leading scientific schools of the Russian Federation (MK-2254.2020.7 "Pharmacogenetic approach to the prevention of complications of antiparkinsonian therapy").
About the Authors
A. A. Tappakhov
M.K. Ammosov North-Eastern Federal University;
Center for Neurodegenerative Diseases, Scientific Center for Complex Medical Problems (Yakutsk)
Russian Federation
Russian Federation
Tappakhov Alexey A. – Candidate of Sciences in Medicine, Associate Professor at the Department of Neurology and Psychiatry of the Medical Institute;
Senior Researcher
T. E. Popova
Scientific Center for Complex Medical Problems (Yakutsk)
Russian Federation
Russian Federation
Popova Tatyana E. – Grand PhD in Medical Sciences, deputy Director for Science
T. G. Govorova
The Clinic of M.K. Ammosov North-Eastern Federal University
Russian Federation
Russian Federation
Govorova Tatiana G. – Candidate of Sciences in Medicine, the Head of laboratory of neuropsychophysiological research
N. A. Shnayder
Center for Personalized Psychiatry and Neurology, V.M. Bekhtereva National Medical Research Center for Psychiatry and Neurology;
Center for Shared Use of Molecular and Cellular Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Shnayder Natalia A. – Grand PhD in Medical Sciences, Professor, Leading Researcher;
Leading Researcher
E. E. Vaiman
Center for Personalized Psychiatry and Neurology, V.M. Bekhtereva National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Vaiman Elena E. – neurologist, junior researcher
R. F. Nasyrova
Центр персонализированной психиатрии и неврологии НМИЦ психиатрии и неврологии им. В.М. Бехтерева
Russian Federation
Russian Federation
References
1. Parkinson's disease: modern approaches to diagnosis and treatment / O.S. Levin, D.V. Artemiev, E.V. Bril [et al.] // Practical medicine. – 2017. – T. 102, No. 1. – P. 45-51.
2. Illarioshkin S.N. Trembling hyperkinesis / S.N. Illarioshkin, I.A. Ivanova-Smolenskaya. - Moscow: Publishing House "Atmosphere". – 2011. – 360 p.
3. Illarioshkin S.N. Amantadine in the treatment of Parkinson's disease / S.N. Illarioshkin // Nervous diseases. – 2016. – No. 3. – P. 14-19.
4. Levin O.S. Levodopa-induced dyskinesias in Parkinson's disease: possibilities of prevention and therapy / O.S. Levin // Modern therapy in psychiatry and neurology. – 2015. – No. 3. – P. 15-25.
5. Titova N.V. Levodopa: the story continues / N.V. Titova, E.A. Katunina // S. S. Korsakov Journal of Neurology and Psychiatry. – 2014. – No. 9. – P. 93-99.
6. Pharmacogenetics of antipsychotic-induced extrapyramidal disorders / N.A. Shnayder, E.E. Vayman, N.G. Neznanov NG [et al]. - St. Petersburg: "Dean" publishing house, 2021. - 288 p.
7. Pharmacogenetics of levodopa-induced dyskinesias in Parkinson's disease / А.А. Tappakhov, T.E. Popova, T.G. Govorova [et al.] // Neurology, neuropsychiatry, psychosomatics. - 2020. - No. 12 (1). - P. 87-92. DOI: 10.14412/2074-2711-2020-1-87-92]
8. Assessment of three essential tremor genetic loci in sporadic Parkinson’s disease in Eastern China / T. Gao, J. Wu, R. Zheng [et al]. // CNS Neurosci Ther. – 2020. – Vol. 26(4). – P. 448-452. DOI:10.1111/cns.13272
9. Association of the DRD2 CAn-STR and DRD3 Ser9Gly polymorphisms with Parkinson’s disease and response to dopamine agonists / S. Xu, J. Liu, X. Yang [et al.] // J Neurol Sci. – 2017. – Vol. 372. – P. 433-438. DOI:10.1016/j.jns.2016.08.005
10. Beaulieu J. The Physiology, Signaling, and Pharmacology of Dopamine Receptors / J. Beaulieu, R. Gainetdinov // Pharmacol Rev. – 2011. – Vol. 63(1). – P. 182-217. DOI:10.1124/pr.110.002642
11. Candidate genes encoding dopamine receptors as predictors of the risk of antipsychotic-Induced parkinsonism and tardive dyskinesia in schizophrenic patients / E.E. Vaiman, N.A. Shnayder, M.A. Novitsky [et al.] // Biomedicines. – 2021. - Vol. 9. - P. 879. DOI: 10.3390/biomedicines9080879
12. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson’s disease / L. De Lau, D. Verbaan, J. Marinus [et al] // Mov Disord. – 2012. – Vol. 27(1). – P. 132-135. DOI: 10.1002/mds.23805
13. Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson’s disease / J.Y. Lee, J. Cho, E.K. Lee [et al.] // Mov Disord. – 2011. – Vol. 26(1). – P. 73-79. DOI:10.1002/mds.23400
14. Dyskinesia in Parkinson’s disease: mechanisms and current non-pharmacological interventions / R. Heumann, R. Moratalla, M. Herrero [et al.] // J Neurochem. – 2014. – Vol. 130(4). – P. 472-489. DOI:10.1111/jnc.12751
15. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease / A. Berardelli, G.K. Wenning, A. Antonini [et al.] // Eur J Neurol. – 2013. – Vol. 20. – P. 16-34. DOI:10.1111/ene.12022
16. Encarnacion E V. Levodopa-induced dyskinesias in Parkinson’s disease: Etiology, impact on quality of life, and treatments / E.V. Encarnacion, R.A. Hauser // Eur Neurol. – 2008. – Vol. 60(2). – P. 57-66. DOI:10.1159/000131893
17. Genetic analysis of “leucine-rich repeat (LRR) and immunoglobulin (Ig) domain-containing, Nogo receptor-interacting protein-1 (LINGO1)” in two independent Chinese parkinson’s disease populations / Y-R. Wu, E-K. Tan, C-M. Chen [et al]. // Am J Med Genet Part B Neuropsychiatr Genet. – 2011. – Vol. 156(1). – P. 99-103. DOI:10.1002/ajmg.b.31124
18. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson’s disease models / H. Inoue, L. Lin, X. Lee [et al.] // Proc Natl Acad Sci. – 2007. – Vol. 104(36). – P. 14430-14435. DOI: 10.1073/pnas.0700901104
19. Lewitt P.A. Levodopa therapy for Parkinson’s disease: Pharmacokinetics and pharmacodynamics / P.A. Lewitt // Mov Disord. – 2015. – Vol. 30(1). – P. 64-72. DOI:10.1002/mds.26082
20. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease / C. Vilariño-Güell, C. Wider, O.A. Ross [et al.] // Neurogenetics. – 2010. – Vol. 11(4). – P. 401-408. DOI: 10.1007/s10048-010-0241-x
21. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease / C. Vilariño-Güell, O.A. Ross, C. Wider [et al.] // Parkinsonism Relat Disord. – 2010. – Vol. 16(2). – P. 109-111. DOI:10.1016/j.parkreldis.2009.08.006
22. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson’s Disease / T. Sampaio, E. dos Santos, G. de Lima [et al.] // J Clin Pharmacol. – 2018. – Vol. 58(7). – P. 920-926. DOI:10.1002/jcph.1096
23. Neznanov N.G. A paradigm shift to treat psychoneurological disorders / N.G. Neznanov // Pers Psychiatry Neurol. – 2021. - Vol. 1(1). - P. 1-2.
24. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy / J.A. Obeso, M. Stamelou, C.G. Goetz [et al.] // Mov Disord. – 2017. – Vol. 32(9). – P. 1264-1310. DOI:10.1002/mds.27115
25. Polymorphisms of dopamine receptor genes and risk of L-dopa–induced dyskinesia in Parkinson’s disease / C. Comi, M. Ferrari, F. Marino [et al.] // Int J Mol Sci. – 2017. – Vol. 18(2). – P. 1-8. DOI:10.3390/ijms18020242
26. Screening for two SNPs of LINGO1 gene in patients with essential tremor or sporadic Parkinson’s disease in Chinese population / X. Zuo, H. Jiang, J. Guo [et al.] // Neurosci Lett. – 2010. – Vol. 481(2). – P. 69-72. DOI:10.1016/j.neulet.2010.06.041
27. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson’s disease / N. Kaplan, A. Vituri, A. Korczyn [et al.] // J Mol Neurosci. – 2014. – Vol. 53(2). – P. 183-188. DOI:10.1007/s12031-014-0276-9
28. Tambasco N. Levodopa in Parkinson’s Disease: Current Status and Future Developments / N. Tambasco, M. Romoli, P. Calabresi // Curr Neuropharmacol. – 2017. – Vol. 16(8). – P. 1239-1252. DOI:10.2174/1570159x15666170510143821
29. Tan E-K. Linking LINGO1 to essential tremor / E-K. Tan // Eur J Hum Genet. – 2010. – Vol. 18(7). – P. 739-740. DOI:10.1038/ejhg.2010.25
30. Vaiman E.E. Pharmacogenetics of chlorpromazine and its role in the development of antipsychotic-induced parkinsonism / E.E. Vaiman, M.A. Novitsky, R.F. Nasyrova // Pers Psychiatry Neurol. – 2021. - Vol. 1(1). - P. 11-17. DOI:10.52667/2712-9179-2021-1-1-11-17
31. Variant in the sequence of the LINGO1 gene confers risk of essential tremor / H. Stefansson, S. Steinberg, H. Petursson [et al.] // Nat Genet. – 2009. – Vol. 41(3). – P. 277-279. DOI:10.1038/ng.299
Review
For citations:
Tappakhov A.A., Popova T.E., Govorova T.G., Shnayder N.A., Vaiman E.E., Nasyrova R.F. Association of single nucleotide variants in the DRD3 and LINGO1 genes with the development of drug dyskinesias in Parkinson's disease: results of a pilot study. Yakut Medical Journal. 2021;(3):9-12. https://doi.org/10.25789/YMJ.2021.75.02
Views:
16
Email this article 